Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785964 · ClinicalTrials.gov registry record · Phase 3
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
A Phase 3 study, sponsored by SpringWorks Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT03785964 is a Phase 3 study that has completed, run by SpringWorks Therapeutics. The registered enrollment target is 142 participants.
The verdict
NCT03785964, a Phase 3 study, has completed, sponsored by SpringWorks Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Nirogacestat oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785964
The ClinicalTrials.gov registry entry for NCT03785964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SpringWorks Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03785964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785964 about?
NCT03785964 is a clinical study titled "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)". This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase...
What is the current status of trial NCT03785964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2019-04-17. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT03785964?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Nirogacestat oral tablet (DRUG).
Who is sponsoring clinical trial NCT03785964?
This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.